CHILDREN'S NASACORT ALLERGY 24HR OTC
Generic Name and Formulations:
Triamcinolone acetonide 55mcg; per nasal spray; scent- and alcohol-free.
Indications for CHILDREN'S NASACORT ALLERGY 24HR:
Seasonal and perennial allergic rhinitis, including nasal congestion.
2 sprays in each nostril once daily. Reduce dose as symptoms improve.
<2yrs: not recommended. 2–<6yrs: 1 spray in each nostril once daily. 6–12yrs: 1 spray in each nostril once daily; max 2 sprays in each nostril once daily. Reduce dose as symptoms improve.
Avoid use in patients with recent nasal ulcers, surgery, or injury that has not healed. Infections (eg, ocular herpes simplex). Glaucoma. Cataracts. Discontinue if exposed to measles, chickenpox, or tuberculosis. Monitor for growth suppression in children. Avoid eyes or mucous membranes. Reevaluate if no improvement after 1 week. Pregnancy. Nursing mothers.
Avoid concomitant other steroid-containing products.
Infection, fever, visual changes, severe or frequent nosebleeds.
Nasal Spray—8.25g (60 sprays), 16.5g (120 sprays); Children's—8.25g (60 sprays)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities